Related Experiment Videos
Peer support for patients with type 2 diabetes: cluster randomised controlled trial.
1Department of Public Health and Primary Care, Trinity College, Dublin, Republic of Ireland. susmith@tcd.ie
BMJ (Clinical Research Ed.)
|February 18, 2011
Summary
Peer support for type 2 diabetes patients in general practice is feasible but not effective. This study found no significant improvements in HbA1c, blood pressure, cholesterol, or wellbeing after two years.
Area of Science:
- Diabetes Management
- Public Health Interventions
- Patient Support Systems
Background:
- Type 2 diabetes requires ongoing management and support.
- Peer support models are being explored to enhance patient care.
- General practice settings offer a potential platform for scalable interventions.
Purpose of the Study:
- To evaluate the effectiveness of a group-based peer support intervention for patients with type 2 diabetes.
- To assess the impact of peer support on clinical outcomes and wellbeing.
- To determine the feasibility of implementing peer support in primary care.
Main Methods:
- A cluster randomised controlled trial involving 395 patients with type 2 diabetes across 20 general practices.
- Intervention group received peer support over two years, including training peer supporters and group meetings.
- Outcomes measured included HbA1c, blood pressure, cholesterol, and wellbeing scores.
Main Results:
- No significant differences were observed between the peer support intervention and control groups at two-year follow-up.
- Key clinical indicators such as HbA1c, systolic blood pressure, and cholesterol concentration showed no significant changes.
- While trends suggested potential improvements in risk factor control, these did not reach statistical significance.
Conclusions:
- Group-based peer support is feasible within general practice for type 2 diabetes patients.
- The tested peer support intervention was not effective in improving clinical outcomes for all patients with type 2 diabetes.
- Results do not currently support widespread adoption of this peer support model.
Related Concept Videos
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...